Ping Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ping Xu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Chengxiang Hou
School of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang, 212018, China; Sericultural Research Institute, Chinese Academy of Agricultural Sciences, Zhenjiang, 212018, China
1 shared publication- Congwu Hu
State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing 400716, China
1 shared publication Cuiying Zhu
Renji Affiliated Hospital, Shanghai Communication University, Shanghai, China
1 shared publicationDengyan Xiao
Guangzhou General Military Hospital, Guangzhou, China
1 shared publicationDingding Lü
Zhenjiang College, Zhenjiang, 212028, China
1 shared publication- He Huang
Nanjing Med Univ, Dept Sports & Joint, Nanjing Hosp, Nanjing Hosp 1, Nanjing 210029, Jiangsu, Peoples R China
1 shared publication
Latest Publications
- 1 July 2021
- Published by Elsevier in Molecular Immunology
- Vol. 135, 204-216
iTRAQ-based quantitative proteomic analysis of silkworm infected with Beauveria bassiana
- 1 July 2021
- Published by Elsevier in Molecular Immunology
- Vol. 135, 204-216
iTRAQ-based quantitative proteomic analysis of silkworm infected with Beauveria bassiana
- 25 September 2014
- Published by Taylor & Francis in Journal of Immunoassay and Immunochemistry
- Vol. 36 (3) , 265-283
Evaluation of the Analytical and Clinical Performances of Time-Resolved Fluoroimmunoassay for Detecting Carcinoma Antigen 50
We developed a TR-FIA kit for quantitative detection of CA50. This study aims to evaluate the analytical and clinical performances of this kit. Precision, accuracy, specificity, sensitivity, stability, and endogenous interference of this kit are evaluated. Reference range is established. Coincidence rate and correlation between TR-FIA and RIA are evaluated. ROC is adopted to evaluate the diagnostic performance. This kit shows excellent precision with a coefficients of variation (CVs) ranged from 2.2–9.3%, accuracy (average recovery, 98.5%), sensitivity (minimum detectable concentration is 0.2 U/mL), specificity (all cross-reactivity is less than 0.1% except CA199, which is 0.175%), and storage stability (recoveries, 90.8–100.4%). Bilirubin, hemoglobin, and triglyceride dose not interfere with CA50 detection (recovery, 97.13–109.1%). The range from 0–25 U/mL is chosen as the reference range. There are good correlation (r = 0.804) and coincidence (p = 0.608, kappa = 0.924) between TR-FIA and RIA. Diagnostic performance of this kits, which based on RIA results, is perfect (AUC = 0.996), and the diagnostic accuracy for malignancy diagnosis is in moderate degree (AUC, 0.802–0.861). The TR-FIA (CA50) kit performs well in analytical and clinical performances, and can be employed in the clinical diagnosis of malignancy.
- 25 September 2014
- Published by Taylor & Francis in Journal of Immunoassay and Immunochemistry
- Vol. 36 (3) , 265-283
Evaluation of the Analytical and Clinical Performances of Time-Resolved Fluoroimmunoassay for Detecting Carcinoma Antigen 50
We developed a TR-FIA kit for quantitative detection of CA50. This study aims to evaluate the analytical and clinical performances of this kit. Precision, accuracy, specificity, sensitivity, stability, and endogenous interference of this kit are evaluated. Reference range is established. Coincidence rate and correlation between TR-FIA and RIA are evaluated. ROC is adopted to evaluate the diagnostic performance. This kit shows excellent precision with a coefficients of variation (CVs) ranged from 2.2–9.3%, accuracy (average recovery, 98.5%), sensitivity (minimum detectable concentration is 0.2 U/mL), specificity (all cross-reactivity is less than 0.1% except CA199, which is 0.175%), and storage stability (recoveries, 90.8–100.4%). Bilirubin, hemoglobin, and triglyceride dose not interfere with CA50 detection (recovery, 97.13–109.1%). The range from 0–25 U/mL is chosen as the reference range. There are good correlation (r = 0.804) and coincidence (p = 0.608, kappa = 0.924) between TR-FIA and RIA. Diagnostic performance of this kits, which based on RIA results, is perfect (AUC = 0.996), and the diagnostic accuracy for malignancy diagnosis is in moderate degree (AUC, 0.802–0.861). The TR-FIA (CA50) kit performs well in analytical and clinical performances, and can be employed in the clinical diagnosis of malignancy.